In vivo, the administration of T3 or T4together with TAA enhances hepatic fibrosis after 3 weeks, compared with theTAA-treated group, accompanied by increased αSMA expression inT3- and T4-treated groups [41], whereas in another study, hepatic fibrosis wassignificantly reduced in hypothyroid rats, either chemically and surgically induced,as compared with euthyroid controls, and was aggravated in TAA-treated hyperthyroidrats [42]. Here, ACTA1 is linked to Hepatic fibrosis.